Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

This publication has 11 references indexed in Scilit:

• Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
  Infectious Diseases and Therapy, 2021
• Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
  The Journal of Infectious Diseases, 2021
• Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
  Nature Communications, 2021
• Anomalous collapses of Nares Strait ice arches leads to enhanced export of Arctic sea ice
  Nature Communications, 2021
• Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
  Nature Microbiology, 2020
• AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
  Clinical Infectious Diseases, 2020
• Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2
  Clinical Pharmacology & Therapeutics, 2020
• An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
  Science Translational Medicine, 2020
• Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
  CPT: Pharmacometrics & Systems Pharmacology, 2020
• Going transparent
  Nature Microbiology, 2019